Ruslana Shumak-Gaeta

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

Tildrakizumab as a Potential Option for Early Psoriatic Arthritis in Patients with Metabolic Comorbidities and Psoriasis: a Case Series.

Tildrakizumab as a Potential Option for Early Psoriatic Arthritis in Patients with Metabolic Comorbidities and Psoriasis: a Case Series.

Journal: Dermatology practical & conceptual

Published: June 12, 2025

Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinics.

Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinics.

Journal: The Journal of dermatological treatment

Published: February 10, 2025

Successful treatment with upadacitinib in concurrent atopic dermatitis, Crohn's disease, alopecia areata, and eosinophilic gastropathy in a pediatric patient.

Successful treatment with upadacitinib in concurrent atopic dermatitis, Crohn's disease, alopecia areata, and eosinophilic gastropathy in a pediatric patient.

Journal: Dermatology reports

Published: October 10, 2024

Efficacy and Safety of Apremilast in Oncological Patients with Moderate-to-Severe Plaque Psoriasis: A 5 years Retrospective Observational Study.

Efficacy and Safety of Apremilast in Oncological Patients with Moderate-to-Severe Plaque Psoriasis: A 5 years Retrospective Observational Study.

Journal: Clinical, cosmetic and investigational dermatology

Published: October 07, 2024

Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study).

Efficacy and safety of tildrakizumab in elderly patients: real-world multicenter study (ESTER - study).

Journal: The Journal of dermatological treatment

Published: February 27, 2024

Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series.

Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series.

Journal: Clinical, cosmetic and investigational dermatology

Published: January 28, 2024

Preliminary Evidence of Efficacy, Safety, and Treatment Satisfaction with Tirbanibulin 1% Ointment: A Clinical Perspective on Actinic Keratoses.

Preliminary Evidence of Efficacy, Safety, and Treatment Satisfaction with Tirbanibulin 1% Ointment: A Clinical Perspective on Actinic Keratoses.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: October 23, 2023

Effect of baricitinib in patients with alopecia areata: Usefulness of trichoscopic evaluation.

Effect of baricitinib in patients with alopecia areata: Usefulness of trichoscopic evaluation.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: September 04, 2023

A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients.

A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: February 06, 2023

Why targeted therapeutics have provided benefit in psoriasis: looking at IL-17 biology.

Why targeted therapeutics have provided benefit in psoriasis: looking at IL-17 biology.

Journal: Expert review of clinical pharmacology

Published: October 03, 2022

Early clinical response to 5-fluorouracil 0.5% and salicylic acid 10% topical solution in the treatment of actinic keratoses of the head: an observational study.

Early clinical response to 5-fluorouracil 0.5% and salicylic acid 10% topical solution in the treatment of actinic keratoses of the head: an observational study.

Journal: The Journal of dermatological treatment

Published: April 18, 2022

Showing 1-11 of 11

Last Updated: 09/26/2026